About: CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 20 May 2016

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2016 (ast) наукова стаття, опублікована в травні 2016 (uk) مقالة علمية نشرت في 20 مايو 2016 (ar) scientific article published on 20 May 2016 (en)
publication date	wds:Q37058098-E2C74DA4-3137-4D71-8F1E-1F9785BCCED7
publication date	2016-05-20 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37058098-D4B66CF8-C588-480A-B315-8380D959D49B
language of work or name	English
cites work	wds:Q37058098-08BDF174-1130-40BD-9A22-CCDFA6A0D365 wds:Q37058098-14A6ECF2-5427-4538-AEB4-004B33CDEC12 wds:Q37058098-175DA533-431A-4F3B-8457-5BB1710E383A wds:Q37058098-1B9A5A85-6630-4510-A486-CCEEAF2EDD54 wds:Q37058098-3E0C5062-E77B-4BC9-92E3-A8894FDA2FDC wds:Q37058098-416F9B48-63AB-48E9-978B-A5A6B0974B7D wds:Q37058098-6D8D0CD1-1519-4370-BAF9-D34F2A396324 wds:Q37058098-77DA7235-9850-4172-BDAE-3573DD2F427C wds:Q37058098-82DA4B18-43FE-4923-990C-584C4BC7E970 wds:Q37058098-8A77DC71-C390-4679-BC22-6B1E17ACA045 wds:Q37058098-92D4D341-D2B3-441C-A331-A2E4D74061E0 wds:Q37058098-9774E64C-8368-4FB0-BDE4-0E810134B0B6 wds:Q37058098-A27AE138-DE2E-4F4D-B106-31C377A97DA2 wds:Q37058098-AE221446-15FA-4D79-8026-E284A0690BCC wds:Q37058098-B5058BF8-8A86-4A82-A351-662DCFBB356C wds:Q37058098-B8E094FB-FCB6-427C-945F-D2709976C4DC wds:Q37058098-B9B5379D-C744-4332-A10B-3D3EF04F269A wds:Q37058098-C862ACB6-9E00-40D0-86DF-675FD1F055AA wds:Q37058098-D0E77427-8D7B-49F4-A8F9-77C00D9F7623 wds:Q37058098-E796F3C7-DEBA-45AD-89C7-3A8E0F131EBD wds:Q37058098-F90C5773-29B8-4005-9CF1-424D053D8A1F
cites work	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Chimeric antigen receptor T cells for sustained remissions in leukemia Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells T-cell immunotherapy: looking forward CD19 CAR Therapy for Acute Lymphoblastic Leukemia
author name string	wds:Q37058098-A2E4779E-7959-47D7-989A-4771E9DDCABC wds:Q37058098-DB901FAF-A4F7-4B00-B12A-FD2AABC141E1
author name string	Jae H Park Renier J Brentjens
rdfs:label	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (en) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (nl) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (ast)
skos:prefLabel	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (en) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (nl) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (ast)
name	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (en) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (nl) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (ast)
author	wds:Q37058098-C00A3000-B34D-40C6-ADBA-65A9FFDDA258
author	Mark Geyer
title	wds:Q37058098-51E5FFFE-0859-48CC-A574-A486697A4AAC
title	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date (en)
page(s)	wds:Q37058098-2F45B650-0FD3-4C08-A3EF-47F7E28B0734
page(s)	3312-3320
instance of	wds:Q37058098-171e1bef-b49f-4a13-b4a7-5d4dbe90d0a0 wds:Q37058098-91ED8C57-6029-498D-94CC-6BB44CC97401
instance of	review article scholarly article
PubMed ID	wds:Q37058098-B05F3679-3A1C-4625-B099-80C9035089C7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27207800
PubMed ID	27207800
published in	wds:Q37058098-E47ADE5D-41CA-48F9-AA35-77C2D9D42E0E
published in	Blood
issue	wds:Q37058098-333CB560-3863-4A4C-B654-42B3BB25DD21
volume	wds:Q37058098-24C9DDCC-D362-4072-9E46-BA726819B6B5
issue	26
volume	127
DOI	wds:Q37058098-7109A954-9B41-4FB3-91F3-82E07A7EB1C1
DOI	http://dx.doi.org/10.1182/BLOOD-2016-02-629063
DOI	10.1182/BLOOD-2016-02-629063
Fatcat ID	wds:Q37058098-AFDB8BFA-AC5A-4B98-B026-F7E6DA76F5C2
Fatcat ID	release_dnqtky3n3jd4rjdommefbxoegu

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software